ANI Pharma (ANIP) Stock Forecast & Price Target

ANI Pharmaceuticals is positioned for attractive long-term growth because its 2Q 2026 results beat expectations on revenue and EPS, with total sales of $266.0M and non-GAAP EPS of $2.21, while generics and brand royalties outperformed and helped offset softer Cortrophin sales. Although Cortrophin was at the low end of guidance and FY 2026 sales guidance was trimmed to $520M-$540M, management still expects roughly 64% of 2026 Cortrophin revenue in 2H26, supported by a 50% sales-force expansion and rising prescriptions that reached an all-time high in 2Q 2026. That combination of a strengthened Rare Disease franchise, stable guidance elsewhere, and a reasonable valuation around a ~$1.78Bn market cap supports a constructive outlook.

ANI Pharmaceuticals is facing a negative outlook because its growth drivers remain vulnerable to clinical, regulatory, manufacturing, and commercial setbacks, especially for Purified Cortrophin Gel, ILUVIEN, and YUTIQ. Generics also appear to be a weakening contributor, with 1Q 2026 revenue of $105.4 million benefiting from a prior partnered launch while management expects FY 2026 Generics revenue to decline modestly year over year as exclusivity lapses and prescription volumes fell 3.8% sequentially in 2Q 2026. On top of that, Alimera integration risk and ongoing pricing and competitive pressure in generics could compress execution and limit upside across its Rare Disease and Brands businesses.